Radiation Therapy and Nivolumab with Relatlimab-rmbw Achieved a Complete Response in Metastatic Cutaneous Melanoma to the Orbit.

We present a patient with left orbital metastasis of cutaneous melanoma, treated with 30 Gy in 10 fraction radiation therapy followed by a combination of programmed death-1 inhibitor, nivolumab, and lymphocyte-activation gene inhibitor, relatlimab. The patient achieved a complete response to treatment, with no evidence of recurrence of the orbital mass, 17 months after treatment initiation.